Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cymbalta in Mild Cognitive Impairment and Depression
NCT02590874Phase 4Completed
- Sponsor
- University of North Texas Health Science Center
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of duloxetine in Mild Cognitive Impairment (MCI), major depressive disorder (MDD), sponsored by University of North Texas Health Science Center. Started Jan 2016; status: completed.
02
Drugs
duloxetine
03
Conditions
Mild Cognitive Impairment (MCI)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02590874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590874.